
Canine Oncology Treatment Data
Intratumoral (IT) administration of MIE-201 has demonstrated durable and systemic antitumor activity as a single agent and in combination treatment regimens in studies of canine patients with several different cancers.
Antitumor Activity Observed in Naturally Occurring Canine Cancers
>25 dogs treated to date
Single Agent
-
Mammary cancer (MC) (unpublished)
-
Inflammatory mammary cancer (IMC)
Combination Treatment
-
Melanoma with radiation
-
IMC with chemotherapy
-
Carcinoma with radiation + hyperthermia

Overall Observations
• Single agent anti-tumor activity
• Combination treatment activity
• Increased recruitment of immune cells into tumors
• Systemic anti-tumor responses (abscopal effect observed)
MIE-201 in Combination with Radiation Demonstrates Durable Complete Tumor Responses in Canine Patients with Oral Melanoma
Study Design
n = 3, 2 weeks radiation + MIE-201
n = 2, 2 weeks radiation only
Results
-
Significant increase in immune cell infiltration of tumors receiving MIE-201
-
All MIE-201 treated canines achieved complete tumor responses with no recurrence
-
Canines receiving radiation alone experienced tumor progression
Hoopes P.J., Wagner R.J.,Duval K., Kang K., Gladstone D.J., Moodie K.L., Crary-Burney M., Ariaspulido H., Veliz F.A., Steinmetz N.F., Fiering S.N. (2018) Treatment of canine oral melanoma with nanotechnology-based immunotherapy and radiation. Mol Pharm., 15, 3717-3722. PMID: 29613803, PMCID: PMC6296751.
Tumor Regressions Observed in Canine Inflammatory Mammary Cancer (IMC) Patients Treated with Two-Week Neoadjuvant in situ MIE-201
Study Design
A: n = 5, Standard of Care (SOC) only, (control)
B: n = 5, 2-week single-agent MIE-201 followed by combination with SOC
Results
-
All MIE-201-treated patients demonstrated reductions in tumor size after roughly two weeks (monotherapy)
-
In two patients, the reduction in tumor size supported a decision to surgically remove the tumor, which is very rare for IMC treatment given IMC’s highly aggressive nature
-
All control patients showed tumor growth during the course of the study
-
Survival of the MIE-201-treated patients was significantly extended (p=0.033) as compared to control patients
-
Increased CD8+ T cells and ratio of CD8+ T cells vs Treg cells in MIE-201 treated patients
-
Increased neutrophil infiltration into tumors in MIE-201 treated patients
-
No toxicities or adverse events were observed using MIE-201 treatment
Daniel Alonso-Miguel, Guillermo Valdivia, Diego Guerrera, Maria Dolores Perez-Alenza, Stanislav Pantelyushin, Angela Alonso-Diez, Veronique Beiss, Steven Fiering, Nicole F Steinmetz, Maria Suarez-Redondo, Johannes Vom Berg, Laura Peña, Hugo Arias-Pulido (2022) Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer. Journal for ImmunoTherapy of Cancer 2022;10:e004044. doi:10.1136/jitc-2021-004044.
If you are a veterinarian interested in learning more about MIE-201 and our plans for its continued development for the treatment of canine cancers, please contact us.